Authors
Shuang Zhang, Jingjing Liu, Ying Liu
Published in
Current opinion in oncology. Oct 09, 2026. Epub Oct 09, 2026.
Abstract
This review summarizes the breakthrough progress in small cell lung cancer (SCLC) treatment driven by innovations in immunotherapy, novel agents, and emerging therapeutic strategies.
Immunotherapy maintenance following induction therapy, which combines immunotherapy and chemotherapy, remains an area requiring breakthroughs to become the standard first-line regimen for extensive-stage SCLC (ES-SCLC). Lurbinectedin plus atezolizumab has emerged as a novel maintenance option that improves overall survival and also is associated with increased toxicity. Exploring intensified maintenance regimens and innovative induction treatment strategies holds promise for improving the efficacy of first-line therapy for ES-SCLC. The T-cell engager tarlatamab has transformed the landscape of relapsed SCLC, where chemotherapy was previously the sole therapeutic option. Multiple antibody-drug conjugates have demonstrated promising antitumor efficacy and manageable safety profiles in preliminary clinical trials for relapsed SCLC, marking the next frontier of therapeutic breakthroughs. Consolidation therapy with durvalumab following concurrent chemoradiotherapy has established a new standard treatment paradigm for limited-stage SCLC. The optimal combinatorial regimen pairing thoracic radiotherapy with immunotherapy for SCLC remains under study.
Over the past decade, the therapeutic landscape of SCLC has undergone a complete transformation, with new standard treatment established for SCLC at frontline and relapsed disease settings.
PMID:
43021706
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0